title: PET/CT enterography in Crohn disease: correlation of disease activity on CT enterography with 18F-FDG uptake.
abstract: We combined (18)F-FDG PET and CT enterography in a single examination and compared the level of (18)F-FDG uptake measured by maximal standardized uptake value (SUVmax) with the CT enterography patterns of disease activity found in patients with Crohn disease (CD).
  
  
  METHODS
  Twenty-eight patients (mean age, 37.5 y; 11 male and 17 female) suspected of having active CD underwent PET/CT enterography. Abnormal bowel segments recognized on CT enterography were graded qualitatively for the presence of perienteric fat infiltration, the comb sign, and intramural attenuation and by quantitative measurements of mural enhancement (Hounsfield units) and thickness (mm). Also, for each patient, normal segments of the ileum and colon were noted, and CT enterography measurements of thickness and enhancement were obtained. For segments detected on CT enterography, a volume of interest was placed on the fused (18)F-FDG PET scan, and the SUVmax was obtained.
  
  
  RESULTS
  Of the 28 patients with suspected active CD, 22 had 85 abnormal segments and 6 had no abnormal segments. SUVmax was significantly higher in the abnormal segments than in the normal segments (5.0 +/- 2.5 [95% confidence interval, 4.5-5.5] and 2.1 +/- 0.69 [95% confidence interval, 1.9-2.2], respectively; P < 0.0001). A good correlation was found between SUVmax with CT enterography measurements of mural thickness and enhancement (P < 0.00001). There was a significant difference in SUVmax between the 3 levels of disease activity found by intramural attenuation, perienteric fat infiltration, and the comb sign on CT enterography. SUVmax was significantly higher when there were intense CT enterography findings of active disease (P < 0.001).
  
  
  CONCLUSIONS
  SUVmax assessment may allow an objective, reliable indication of the grade and severity of inflammation activity in abnormal segments of the bowel detected by CT enterography.
authors.affiliation: Department of Nuclear Medicine, Rabin Medical Center, Petah Tikva, Israel. davidgr2@clalit.org.il
authors.forename: David
authors.initials: D
authors.lastname: Groshar
authors.forename: Hanna
authors.initials: H
authors.lastname: Bernstine
authors.forename: Dorit
authors.initials: D
authors.lastname: Stern
authors.forename: Jacob
authors.initials: J
authors.lastname: Sosna
authors.forename: Merab
authors.initials: M
authors.lastname: Eligalashvili
authors.forename: Evren G
authors.initials: EG
authors.lastname: Gurbuz
authors.forename: Yaron
authors.initials: Y
authors.lastname: Niv
authors.forename: Gerald
authors.initials: G
authors.lastname: Fraser
mesh_terms: D000273:Adipose Tissue / Q000000981:diagnostic imaging; D000293:Adolescent; D000328:Adult; D000368:Aged; D001834:Body Water / Q000000981:diagnostic imaging; D003424:Crohn Disease / Q000000981:diagnostic imaging*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics; D006801:Humans; D007422:Intestines / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D012015:Reference Standards; D014057:Tomography, X-Ray Computed; D055815:Young Adult
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18